2. December 2021 - MPH Health Care AG: result Q3-2021

investor news

Preliminary IFRS result for the third quarter of 2021 published. Equity (net asset value) amounts to 190.9 million euros. This corresponds to 44.59 euros per share.

Berlin, December 2, 2021: MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS result for the third quarter of 2021.

According to this, the equity of the investment company amounts to 190.90 million euros as of 30 September 2021 (30 September 2020: 194.39 million euros). The net asset value (NAV) per share as of 30.09.2021 is 44.59 euros (30.09.2010: 45.40 euros).

The equity ratio as of 30.09.2021 has increased to 97.1% (31.12.2020: 95.5%). The main reason for this is the reduction in current and non-current liabilities, which were reduced by 40% compared to the last balance sheet date of 31 December 2020.

The preliminary IFRS net loss for the period for the first nine months of the 2021 financial year amounts to Euro -10.36 million (30.09.2020: Euro -77.25 million). The reason for the net loss for the period is essentially to be found in the fair value measurement of the share prices of the investments as of 30 September 2021 compared with the share prices from 31 December 2020. While the share price of the investment CR Capital AG increased slightly, the share price of the investment M1 Kliniken AG declined disproportionately and could not yet reach the level of the previous year, although the number of treatments in the beauty segment is rising continuously.

EBITDA of M1 Kliniken AG in Q3-2021 totaled EUR 13.3 million (previous year: EUR 8.8 million), while the operating result (EBIT) reached EUR 9.1 million (previous year: EUR 5.8 million). Business development in the Beauty segment was very pleasing. With almost 85 thousand treatments in the 3rd quarter (previous year: 77 thousand), the value from the previous quarters was exceeded. Turnover in the Beauty segment rose to a good 37 million euros (previous year: 28 million euros) and is thus in line with the forecast of approx. 50 million euros for 2021. By the end of the year, the company will be operating a total of 47 specialist centers in Germany and abroad and will thus almost achieve the target it has set itself (50 specialist centers). Four more openings are already planned for the 1st quarter of 2022.

Our second listed participation CR Capital AG was also able to continue on its successful path in 2021 and continue to grow profitably. For the 2021 financial year, EBIT is expected to rise to around 65 million euros (2020 financial year: 51.2 million euros). CR Capital AG does not publish a quarterly report. 

“We are confident about the further development of our listed investment M1 Kliniken AG despite this year’s decline in the share price. The direct participation M1 is developing positively in operational terms. At HAEMATO AG, in which M1 Kliniken AG holds over 50% of the shares, important measures are also being implemented to expand the product portfolio and increase earnings. As a result of the strong nine-month figures for 2021 and the order intake achieved to date, HAEMATO confirms the forecast for the full year, which was raised in August 2021, with annual sales of 280 million euros to 300 million euros and EBIT of 9 million to 11 million euros. In order to further expand the private label segment, an exclusive licence and supply agreement for a well-known botulinum toxin product was concluded with the pharmaceutical company Huons BioPharma Co., Ltd. in South Korea on 25 October 2021. Both parties are planning a European approval procedure for the product in Europe. By distributing a botulinum toxin product under its own brand throughout Europe, HAEMATO is further expanding its “Lifestyle & Aesthetics” business area,” says Patrick Brenske, MPH board member.